Navigation Links
Arete Therapeutics Bolsters Management Team

Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery

HAYWARD, Calif., Oct. 29 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D. Euan MacIntyre, Ph.D., to the newly-created position of Senior Vice President, Drug Discovery. Dr. MacIntyre brings over 20 years of pharmaceutical drug discovery and development leadership to Arete Therapeutics.

"We are extremely pleased to welcome Euan as a member of our executive management team, as his broad drug discovery expertise and disease-specific knowledge will bolster our ability to develop effective s-EH inhibitors," said James H. Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "Given his scientific accomplishments and exceptional track record in advancing discovery programs through clinical development, I am confident Euan will provide invaluable insights and leadership as we finalize our plans to initiate a phase II study of AR9281 to treat metabolic syndrome and build out our expertise in this unique area of biology."

Dr. MacIntyre comes to Arete after more than 22 years with Merck Research Laboratories, where he held positions of escalating importance, most recently as Vice President of Pharmacology. Under his leadership, Dr. MacIntyre's team identified and validated several compounds now commercially available or in clinical trials for a variety of diseases and conditions including emesis, diabetes, obesity, hypertension, hyperlipidemia, pain, urinary incontinence and immuno-inflammatory disorders. In addition to his experience in discovery and development, Dr. MacIntyre evaluated numerous in-licensing candidates and served as a member of several joint research committees for Merck's joint ventures and collaborations. Dr. MacIntyre received his Ph.D. in pharmacology and experimental pathology from the University of Cambridge. He was a post-doctoral fellow at the University of Cambridge and at Harvard Medical School before joining the faculty at his alma mater, the University of Glasgow. He holds several patents, is the author of approximately 150 peer-reviewed publications, and has presented at numerous national and international symposia.

About Arete Therapeutics Inc.

Arete Therapeutics is a well-funded, privately-held pharmaceutical company dedicated to the discovery and development of novel drugs to treat metabolic, inflammatory and cardiovascular disease. It is the world's leading company focused on s-EH (soluble epoxide hydrolase), an important enzyme for the metabolism of arachidonic acid, that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The company was founded by Dr. Bruce Hammock at the University of California, Davis, who discovered s-EH. To date, Arete has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more information on Arete Therapeutics, please visit

SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
2. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
7. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
8. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
9. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Capacitive Fingerprint Sensors - Technology and Patent ... --> --> Fingerprint ... especially in smartphones. The fingerprint sensor vendor Idex forecasts ... sensor units in mobile devices and of the fingerprint ...
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
Breaking Biology News(10 mins):